Gait and attentional performance in freezers under methylphenidate.
Identifieur interne : 000355 ( PubMed/Checkpoint ); précédent : 000354; suivant : 000356Gait and attentional performance in freezers under methylphenidate.
Auteurs : A. Delval [France] ; C. Moreau [France] ; S. Bleuse [France] ; D. Guehl [France] ; E. Bestaven [France] ; E. Guillaud [France] ; K. Dujardin [France] ; L. Defebvre [France] ; D. Devos [France]Source :
- Gait & posture [ 1879-2219 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Dopamine Uptake Inhibitors, Methylphenidate.
- complications : Parkinson Disease.
- drug effects : Attention.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- etiology : Gait Disorders, Neurologic.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Attentional resources appear to be involved in the occurrence of FoG. The Parkgait study recently reported that methylphenidate reduces gait hypokinesia and freezing of gait (FoG) in advanced PD patients receiving STN-DBS in the off-dopaminergic drug condition. Methylphenidate is considered to improve attention. The primary objective of the present ancillary study was to determine whether methylphenidate reduced the interference between a cognitive task and gait in patients with FoG. The study's secondary objective was to compare attentional performance in methylphenidate-treated and placebo-treated patients.
DOI: 10.1016/j.gaitpost.2014.10.022
PubMed: 25468682
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25468682Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gait and attentional performance in freezers under methylphenidate.</title><author><name sortKey="Delval, A" sort="Delval, A" uniqKey="Delval A" first="A" last="Delval">A. Delval</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center, France. Electronic address: arnaud.delval@chru-lille.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Moreau, C" sort="Moreau, C" uniqKey="Moreau C" first="C" last="Moreau">C. Moreau</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Bleuse, S" sort="Bleuse, S" uniqKey="Bleuse S" first="S" last="Bleuse">S. Bleuse</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Guehl, D" sort="Guehl, D" uniqKey="Guehl D" first="D" last="Guehl">D. Guehl</name><affiliation wicri:level="3"><nlm:affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Bordeaux 2 University, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bestaven, E" sort="Bestaven, E" uniqKey="Bestaven E" first="E" last="Bestaven">E. Bestaven</name><affiliation wicri:level="3"><nlm:affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Bordeaux 2 University, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Guillaud, E" sort="Guillaud, E" uniqKey="Guillaud E" first="E" last="Guillaud">E. Guillaud</name><affiliation wicri:level="3"><nlm:affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Bordeaux 2 University, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France; EA 1046, Department of Pharmacology, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France; EA 1046, Department of Pharmacology, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25468682</idno><idno type="pmid">25468682</idno><idno type="doi">10.1016/j.gaitpost.2014.10.022</idno><idno type="wicri:Area/PubMed/Corpus">000398</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000398</idno><idno type="wicri:Area/PubMed/Curation">000394</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000394</idno><idno type="wicri:Area/PubMed/Checkpoint">000394</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000394</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Gait and attentional performance in freezers under methylphenidate.</title><author><name sortKey="Delval, A" sort="Delval, A" uniqKey="Delval A" first="A" last="Delval">A. Delval</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center, France. Electronic address: arnaud.delval@chru-lille.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Moreau, C" sort="Moreau, C" uniqKey="Moreau C" first="C" last="Moreau">C. Moreau</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Bleuse, S" sort="Bleuse, S" uniqKey="Bleuse S" first="S" last="Bleuse">S. Bleuse</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Guehl, D" sort="Guehl, D" uniqKey="Guehl D" first="D" last="Guehl">D. Guehl</name><affiliation wicri:level="3"><nlm:affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Bordeaux 2 University, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bestaven, E" sort="Bestaven, E" uniqKey="Bestaven E" first="E" last="Bestaven">E. Bestaven</name><affiliation wicri:level="3"><nlm:affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Bordeaux 2 University, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Guillaud, E" sort="Guillaud, E" uniqKey="Guillaud E" first="E" last="Guillaud">E. Guillaud</name><affiliation wicri:level="3"><nlm:affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Bordeaux 2 University, UMR 5293, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><affiliation wicri:level="1"><nlm:affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France; EA 1046, Department of Pharmacology, Lille University Medical Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France; EA 1046, Department of Pharmacology, Lille University Medical Center</wicri:regionArea><wicri:noRegion>Lille University Medical Center</wicri:noRegion><wicri:noRegion>Lille University Medical Center</wicri:noRegion></affiliation></author></analytic><series><title level="j">Gait & posture</title><idno type="eISSN">1879-2219</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Attention (drug effects)</term><term>Dopamine Uptake Inhibitors (therapeutic use)</term><term>Female</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (etiology)</term><term>Humans</term><term>Male</term><term>Methylphenidate (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Uptake Inhibitors</term><term>Methylphenidate</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Attention</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Attentional resources appear to be involved in the occurrence of FoG. The Parkgait study recently reported that methylphenidate reduces gait hypokinesia and freezing of gait (FoG) in advanced PD patients receiving STN-DBS in the off-dopaminergic drug condition. Methylphenidate is considered to improve attention. The primary objective of the present ancillary study was to determine whether methylphenidate reduced the interference between a cognitive task and gait in patients with FoG. The study's secondary objective was to compare attentional performance in methylphenidate-treated and placebo-treated patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25468682</PMID><DateCreated><Year>2015</Year><Month>04</Month><Day>03</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2219</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Gait & posture</Title><ISOAbbreviation>Gait Posture</ISOAbbreviation></Journal><ArticleTitle>Gait and attentional performance in freezers under methylphenidate.</ArticleTitle><Pagination><MedlinePgn>384-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gaitpost.2014.10.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0966-6362(14)00748-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Attentional resources appear to be involved in the occurrence of FoG. The Parkgait study recently reported that methylphenidate reduces gait hypokinesia and freezing of gait (FoG) in advanced PD patients receiving STN-DBS in the off-dopaminergic drug condition. Methylphenidate is considered to improve attention. The primary objective of the present ancillary study was to determine whether methylphenidate reduced the interference between a cognitive task and gait in patients with FoG. The study's secondary objective was to compare attentional performance in methylphenidate-treated and placebo-treated patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 24 patients (from two centers) were included in the study. Patients were randomly assigned 1:1 to a three-month course of methylphenidate (1mg/kg/day) or placebo. Patients were assessed after an acute L-dopa challenge. The primary outcome criterion was the stride length ratio ((dual-task stride length minus free gait stride length)/free gait stride length). Trials with FoG episodes were excluded from the analysis. Secondary outcomes included changes in reaction times for computerized attention tasks and FoG severity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">When comparing patients receiving methylphenidate with those receiving placebo, we did not observe any significant differences in the interaction between the dual task and gait or in attentional performance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As in the main Parkgait study, methylphenidate did not reduce gait hypokinesia in patients receiving dopaminergic treatment. Our present results suggest that the reduction in the number of FoG episodes previously observed in patients on methylphenidate was neither due to interaction between a dual-task and gait nor an increase in attentional performance.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delval</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center, France. Electronic address: arnaud.delval@chru-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleuse</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lille University, France; EA 1046, Department of Clinical Neurophysiology, Lille University Medical Center, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guehl</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bestaven</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillaud</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bordeaux 2 University, UMR 5293, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Lille University, France; EA 1046, Department of Neurology and Movement Disorders, Lille University Medical Center, France; EA 1046, Department of Pharmacology, Lille University Medical Center, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gait Posture</MedlineTA><NlmUniqueID>9416830</NlmUniqueID><ISSNLinking>0966-6362</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>207ZZ9QZ49</RegistryNumber><NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018765" MajorTopicYN="N">Dopamine Uptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008774" MajorTopicYN="N">Methylphenidate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Dopamine</Keyword><Keyword MajorTopicYN="N">Freezing of gait</Keyword><Keyword MajorTopicYN="N">Gait</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25468682</ArticleId><ArticleId IdType="pii">S0966-6362(14)00748-6</ArticleId><ArticleId IdType="doi">10.1016/j.gaitpost.2014.10.022</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Delval, A" sort="Delval, A" uniqKey="Delval A" first="A" last="Delval">A. Delval</name></noRegion><name sortKey="Bestaven, E" sort="Bestaven, E" uniqKey="Bestaven E" first="E" last="Bestaven">E. Bestaven</name><name sortKey="Bleuse, S" sort="Bleuse, S" uniqKey="Bleuse S" first="S" last="Bleuse">S. Bleuse</name><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><name sortKey="Devos, D" sort="Devos, D" uniqKey="Devos D" first="D" last="Devos">D. Devos</name><name sortKey="Dujardin, K" sort="Dujardin, K" uniqKey="Dujardin K" first="K" last="Dujardin">K. Dujardin</name><name sortKey="Guehl, D" sort="Guehl, D" uniqKey="Guehl D" first="D" last="Guehl">D. Guehl</name><name sortKey="Guillaud, E" sort="Guillaud, E" uniqKey="Guillaud E" first="E" last="Guillaud">E. Guillaud</name><name sortKey="Moreau, C" sort="Moreau, C" uniqKey="Moreau C" first="C" last="Moreau">C. Moreau</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000355 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000355 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25468682
|texte= Gait and attentional performance in freezers under methylphenidate.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25468682" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |